Nuvectis Pharma, Inc. Common Stock NVCT
i
Market datapartial · fetched 2026-11-12T02:47:37.028Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:26:18.358055959Z
FundamentalsAlpha Vantage · unavailable
Nuvectis Pharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.89 | 115.8% | 20.4% | 16.71 | 182.1% | 23.4% |
| 25Δ | 24.04 | 106.7% | 16.7% | 17.93 | 147.9% | 17.7% |
| 30Δ | 23.19 | 97.5% | 13.1% | 19.15 | 113.7% | 12.0% |
| 35Δ | 22.42 | 90.6% | 10.0% | 20.15 | 92.8% | 7.9% |
| 40Δ | 22.02 | 93.9% | 9.1% | 20.66 | 102.0% | 7.4% |
| 45Δ | 21.61 | 97.1% | 8.2% | 21.16 | 111.1% | 6.9% |
| 50Δ | 21.20 | 100.3% | 7.3% | 21.66 | 120.2% | 6.4% |
| 55Δ | 20.79 | 103.6% | 6.4% | 22.16 | 129.3% | 5.9% |
| 60Δ | 20.38 | 106.8% | 5.5% | 22.61 | 132.7% | 5.4% |
| 65Δ | 19.94 | 111.1% | 4.6% | 22.98 | 123.6% | 4.6% |
| 70Δ | 19.13 | 128.5% | 4.2% | 23.34 | 114.5% | 3.8% |
| 75Δ | 18.31 | 146.0% | 3.8% | 23.71 | 105.3% | 3.0% |
| 80Δ | 17.50 | 163.4% | 3.3% | 24.07 | 96.2% | 2.2% |
20Δ
- Pseudo strike
- 24.89
- IV
- 115.8%
- B/E move
- 20.4%
- Pseudo strike
- 16.71
- IV
- 182.1%
- B/E move
- 23.4%
25Δ
- Pseudo strike
- 24.04
- IV
- 106.7%
- B/E move
- 16.7%
- Pseudo strike
- 17.93
- IV
- 147.9%
- B/E move
- 17.7%
30Δ
- Pseudo strike
- 23.19
- IV
- 97.5%
- B/E move
- 13.1%
- Pseudo strike
- 19.15
- IV
- 113.7%
- B/E move
- 12.0%
35Δ
- Pseudo strike
- 22.42
- IV
- 90.6%
- B/E move
- 10.0%
- Pseudo strike
- 20.15
- IV
- 92.8%
- B/E move
- 7.9%
40Δ
- Pseudo strike
- 22.02
- IV
- 93.9%
- B/E move
- 9.1%
- Pseudo strike
- 20.66
- IV
- 102.0%
- B/E move
- 7.4%
45Δ
- Pseudo strike
- 21.61
- IV
- 97.1%
- B/E move
- 8.2%
- Pseudo strike
- 21.16
- IV
- 111.1%
- B/E move
- 6.9%
50Δ
- Pseudo strike
- 21.20
- IV
- 100.3%
- B/E move
- 7.3%
- Pseudo strike
- 21.66
- IV
- 120.2%
- B/E move
- 6.4%
55Δ
- Pseudo strike
- 20.79
- IV
- 103.6%
- B/E move
- 6.4%
- Pseudo strike
- 22.16
- IV
- 129.3%
- B/E move
- 5.9%
60Δ
- Pseudo strike
- 20.38
- IV
- 106.8%
- B/E move
- 5.5%
- Pseudo strike
- 22.61
- IV
- 132.7%
- B/E move
- 5.4%
65Δ
- Pseudo strike
- 19.94
- IV
- 111.1%
- B/E move
- 4.6%
- Pseudo strike
- 22.98
- IV
- 123.6%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- 19.13
- IV
- 128.5%
- B/E move
- 4.2%
- Pseudo strike
- 23.34
- IV
- 114.5%
- B/E move
- 3.8%
75Δ
- Pseudo strike
- 18.31
- IV
- 146.0%
- B/E move
- 3.8%
- Pseudo strike
- 23.71
- IV
- 105.3%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 17.50
- IV
- 163.4%
- B/E move
- 3.3%
- Pseudo strike
- 24.07
- IV
- 96.2%
- B/E move
- 2.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 91.22% | |
| 86.95% | |
| 86.83% | |
| 95.07% | |
| 93.78% | |
| 92.67% | |
| 87.87% | |
| 91.34% | |
| 99.14% | |
| 89.05% |
Biotechnology
OABI
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology…
More →OBIO
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New…
More →OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →OCS
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug,…
More →OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company…
More →